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AIDS/HIV

The recently completed HIV prevention trials network study 052 is a landmark collaboration
demonstrating that HIV transmission in discordant couples can be dramatically reduced by
treating the infected individual with antiretroviral therapy (ART). However, the cellular and
virological events that occur in the female reproductive tract (FRT) during ART that result in
such a drastic decrease in transmission were not studied and remain unknown. Here, we
implemented an in vivo model of ART in BM/liver/thymus (BLT) humanized mice in order to
better understand the ability of ART to prevent secondary HIV transmission. We
demonstrated that the entire FRT of BLT mice is reconstituted with human CD4+ cells that
are shed into cervicovaginal secretions (CVS). A high percentage of the CD4+ T cells in the
FRT and CVS expressed CCR5 and therefore are potential HIV target cells. Infection with
HIV increased the numbers of CD4+ and CD8+ T cells in CVS of BLT mice. Furthermore,
HIV was present in CVS during infection. Finally, we evaluated the effect of ART on HIV
levels in the FRT and CVS and demonstrated that ART can efficiently suppress cell-free
HIV-RNA in CVS, despite residual levels of HIV-RNA+ cells in both the FRT and CVS.

Find the latest version:
http://jci.me/64212/pdf
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The recently completed HIV prevention trials network study 052 is a landmark collaboration demonstrating that HIV
transmission in discordant couples can be dramatically reduced by treating the infected individual with antiretroviral therapy
(ART). However, the cellular and virological events that occur in the female reproductive tract (FRT) during ART that result
in such a drastic decrease in transmission were not studied and remain unknown. Here, we implemented an in vivo model
of ART in BM/liver/thymus (BLT) humanized mice in order to better understand the ability of ART to prevent secondary HIV
transmission. We demonstrated that the entire FRT of BLT mice is reconstituted with human CD4+ cells that are shed into
cervicovaginal secretions (CVS). A high percentage of the CD4+ T cells in the FRT and CVS expressed CCR5 and therefore are
potential HIV target cells. Infection with HIV increased the numbers of CD4+ and CD8+ T cells in CVS of BLT mice. Furthermore,
HIV was present in CVS during infection. Finally, we evaluated the effect of ART on HIV levels in the FRT and CVS and
demonstrated that ART can efficiently suppress cell-free HIV-RNA in CVS, despite residual levels of HIV-RNA+ cells in both
the FRT and CVS.

Introduction

Most clinical trials of HIV prevention have aimed at preventing HIV
acquisition by topical or systemic administration of preventative
antiretroviral drugs to uninfected individuals (1–10). Results from
these clinical trials have shown either partial or no protection. The
basis for these discordant results are not yet clear and have been
postulated to be due to a combination of a lack of adherence and
inadequate drug levels at the site of exposure (5, 7, 11). In contrast,
the HIV prevention trials network study 052 (HPTN 052) demonstrated 93% protection against secondary heterosexual transmission when infected individuals received early antiretroviral therapy
(ART) (12). Importantly, no linked partner infections were observed
when the HIV-infected participant was stably suppressed by ART.
The prevailing hypothesis for the success of HPTN 052 is that ART
reduces genital cell–free and/or genital cell–associated HIV to levels
that are too low to support HIV transmission (12). This hypothesis
is supported by observational studies suggesting a strong correlation between plasma/genital HIV-RNA levels and risk of heterosexual transmission (13, 14); it is also supported by the ability of
ART to decrease the genital levels of HIV in both men and women
(15–17). There is very limited data in the literature to determine
whether transmission occurs from cell-free virus only or if produc-
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tively infected cells themselves can transmit HIV in the absence of
cell-free virions (18).
In order to better understand the ability of ART to prevent secondary transmission of HIV, we used a small animal model of HIV
infection to further characterize key virological and immunological
events that occur in the female reproductive tract (FRT) during ART.
We designed the following experiments using BM/liver/thymus
humanized mice (BLT mice). First, we performed a detailed and
comprehensive phenotypic characterization of the human lymphocyte subsets present in the FRT and cervicovaginal secretions
(CVS). Next, we analyzed HIV levels and cellular dynamics in CVS
during HIV infection. Finally, we evaluated virological suppression
and cellular dynamics in the FRT and CVS during ART. We provide
data demonstrating that HIV replication occurs in CVS soon after
exposure and continues during the course of infection. This is followed by an increase of CD4+ T cells in CVS, providing additional
target cells for infection. This CD4+ T cell increase is followed by
a delayed increase of CD8+ T cells in CVS. Surprisingly, despite
the strong suppressive effect of ART on the viral load in CVS, HIVRNA+ cells were still present in both the FRT and CVS. However,
when analyzed ex vivo, cells isolated from the FRT and CVS of
ART-suppressed BLT mice did not transmit HIV in a coculture
assay. Thus, our results provide in vivo evidence supporting the
hypothesis behind the success of HPTN 052 (12) for limiting sexual
transmission from HIV-infected women.

Results

Reconstitution of the FRT of BLT mice with human CD4+ cells. BLT
mice were prepared as previously described (19–23) and were
well reconstituted with human hematopoietic cells (CD45+) in
peripheral blood (PB) (median 70%, range 22–95, interquartile
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range 56–78, n = 142). In addition, we used IHC to assess reconstitution and distribution of HIV target cells (human CD4+ cells,
CD68+ myeloid/immature DC, and CD11c+ DCs) in the FRT of
BLT mice (Figure 1 and Supplemental Figures 1 and 2; supplemental material available online with this article; doi:10.1172/
JCI64212DS1). Human CD4+ cells were observed throughout the
FRT. Specifically, in the vagina, human CD4+ cells were mainly
observed in the lamina propria, while few CD4+ cells were present
in the epithelium. Vaginal CD4+ cells were dispersed throughout
the lamina propria both as single cells and as focal aggregates in
close proximity to the epithelial layer, similar to their distribution in healthy women (24, 25). Cervical CD4+ cells were present
as single cells close to the epithelium and distributed throughout
the lamina propria. In the uterine endometrium, CD4+ cells were
found in the stroma both as small clusters closely adjacent to the
epithelial layer and scattered as single cells, resembling their distribution in women (24–26). Similarly, inspection of the FRT for
the presence of human macrophages and DCs demonstrated that,
like in humans, these cell types are dispersed throughout the lamina propria of the vagina, cervix, and uterus (refs. 24, 26–28, and
Supplemental Figures 1 and 2). Furthermore, like in women, macrophages and DCs in BLT mice were more abundant in the cervical mucosa than the vaginal mucosa (24). Together, these results
show the efficient repopulation and adequate distribution of the
human target cells postulated to be involved in vaginal HIV transmission throughout the entire FRT of BLT mice (29).
The majority of human T cells in the FRT and CVS of BLT mice
express a memory phenotype and the CCR5 HIV coreceptor. After
establishing the presence and distribution of human CD4+ cells
in the FRT of BLT mice (Figure 1), we proceeded to compare their
cell surface phenotype to those from PB and CVS (Figure 2). CVS
samples from BLT mice were collected, and cells were isolated
for analysis. Cells were also isolated from the entire FRT. CVS
and FRT samples were then analyzed for the presence of human
CD4+ and CD8+ T cells and compared with samples obtained
from PB (Figure 2, A and B). Our results show that, in all 3 compartments, the majority of human (CD45+) hematopoietic cells
were CD4+ T cells (Figure 2, A and B) and that the level of CD4+
T cells in all 3 compartments was the same prior to infection with
HIV (Figure 2B) (PB vs. FRT, P = 0.22; PB vs. CVS, P = 0.22; and
CVS vs. FRT, P = 0.22). In addition, when compared with PB
T cells, a significantly higher percentage of cells in the FRT and
CVS expressed CCR5, the primary HIV coreceptor involved in
mucosal HIV transmission (ref. 30 and Figure 2C) (CD4+ T cells:
FRT vs. PB, P = 0.01, and CVS vs. PB, P < 0.0001; CD8+ T cells:
FRT vs. PB, P = 0.01, and CVS vs. PB, P < 0.0001). This is consistent with what has been observed in women and with the preferential mucosal transmission of CCR5-tropic HIV (31, 32).
To confirm that cells in the FRT of BLT mice have a similar
memory phenotype as in women (24, 33, 34), we characterized the
naive-memory phenotype of T cell subsets in PB, the FRT, and CVS
(naive: CD45RA+CD27+; central memory (CM): CD45RA–CD27+;
effector memory (EM): CD45RA–CD27–)(Figure 2, D and E). The
majority of CD4+ and CD8+ human T cells in PB of BLT mice had
a naive phenotype (CD45RA+CD27+) (CD4+ T cells: naive vs. CM,
P < 0.0001, and naive vs. EM, P < 0.0001; CD8+ T cells: naive vs.
CM, P < 0.0001, and naive vs. EM, P < 0.0001). In contrast, the
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majority of human T cells in CVS had a CM phenotype (CD4+ and
CD8+ T cells: CM vs. naive, P < 0.0001, and CM vs. EM, P < 0.0001).
Also notable were significantly higher levels of CD4+ EM T cells
(CD45RA–CD27–) in CVS and the FRT compared with PB (Figure 2D)
(EM cells in FRT vs. PB, P = 0.022 and CVS vs. PB, P < 0.0001) and
of CD8+ EM T cells in CVS compared with PB (P < 0.0001) (Figure
2E). Increasing evidence suggests that CD4+ T cells expressing the
integrin α4β7 heterodimer (a mucosal homing receptor) are especially susceptible to HIV infection and may play a central role in the
earliest steps of transmission (35, 36). Therefore, we investigated the
expression of α4β7 on memory CD4+ T cells in PB of humans and PB,
FRT, and CVS of BLT mice. The percentage of memory CD4+ T cells
in PB expressing α4β7 was similar in humans and BLT mice (Supplemental Figure 3). Furthermore, memory CD4+ T cell expression of
α4β7 in the FRT and CVS of BLT mice was significantly lower than in
PB (PB vs. FRT, P = 0.003, and PB vs. CVS, P < 0.0001) (Supplemental Figure 3), which is similar to what is observed in women, where
fewer FRT memory CD4+ T cells express α4β7 when compared with
PB (32). We also observed no difference in CD4+ memory T cell
α4β7 expression between the FRT and CVS of BLT mice (P = 0.13)
(Supplemental Figure 3). In summary, the majority of lymphocytes
in the FRT and CVS of BLT mice were memory T cells expressing
CCR5, which is remarkably similar to what is observed in the FRT of
humans (32, 33, 37).
HIV and HIV-infected cells are present in the FRT and CVS of
BLT mice. We established that HIV-infected cells are present
in the FRT of HIV-infected BLT mice by analyzing different
regions of the FRT from a BLT mouse infected vaginally with
HIV-1JR-CSF, a well-characterized T cell tropic isolate that utilizes
CCR5 as a coreceptor for entry (ref. 38 and Figure 3A). HIV-RNA
was also readily detected in CVS from infected mice (Figure 3,
B–D). As seen in humans, there was an overall significant positive linear correlation between the viral load in plasma and CVS
(Spearman’s correlation coefficient = 0.55 [95% CI, 0.36–0.69,
P < 0.001, n = 51]) (Figure 3E and refs. 31, 39–42).
HIV infection results in a dramatic reduction in the percentage of CD4+ T cells in the FRT and CVS. Following HIV infection, mucosal tissues like the gut undergo a rapid depletion of
CD4+ T cells (43), and this hallmark of HIV infection is faithfully recapitulated in BLT mice (20, 21). A significant decrease
in the percentage of cervical CD4+ T cells during chronic HIV
infection in women has also been observed (31–33, 37, 44). In
order to investigate these phenomena in the FRT and CVS of
BLT mice, we analyzed CD4+ T cell levels longitudinally after
HIV vaginal exposure. Prior to HIV infection, the levels of CD4+
T cells were similar in the FRT, CVS, and PB (Figure 2B and Figure 4, A–D). After vaginal infection, there was a decline in the
levels of human CD4+ T cells in all 3 compartments (Figure 4, A
and D). Specifically, a modest decline to approximately 70% was
observed in the PB, whereas CD4+ T cell levels in CVS incurred a
significantly more dramatic decrease to approximately 5% (for
weeks 3–7, P = 0.0001–0.0042). Interestingly, the levels of CD4+
T cells in the FRT also declined but stabilized at about 30%, an
intermediate level between PB and CVS (Figure 4, A and D).
HIV infection after mucosal exposure occurs by 3 main routes:
rectal, vaginal, and oral. BLT mice are an outstanding model for
each of these individual modes of transmission (20–23, 45–48). In
jci.org   Volume 126   Number 3   March 2016
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Figure 1. Human CD4+ T cells are present throughout the FRT of BLT mice. Immunohistochemical analysis of the entire FRT of a HIV– BLT mouse demonstrates the presence of CD4+ cells in the vagina, cervix, and uterus. CD4+ cells are stained brown. Scale bars: 100 μm.

order to understand the cellular dynamics that occur in the FRT
after local versus distal HIV infection, we evaluated all 3 modes
of mucosal HIV acquisition following exposure to cell-free and/or
cell-associated HIV (Supplemental Table 1). Specifically, to complement the data presented above obtained after vaginal exposure,
we analyzed the levels of human CD4+ T cells in PB, FRT, and CVS
following rectal and oral HIV exposures (Figure 4, B–D). Longitudinal analysis demonstrated a decrease in the percentage of CD4+ T
cells in the FRT and CVS following rectal and oral infection (Figure
4, B–D). Moreover, as in the case of vaginal infection, there was a
significant decrease in the levels of CD4+ T cells in CVS when compared with PB (rectal infection weeks 2–9, P = 0.049–0.002; oral
infection weeks 1–6, P = 0.0016–0.0001). Regardless of the route
of infection (vaginal, rectal, or oral) or type of inoculum (cell-free
or cell-associated virus), there was a greater decrease in the levels
of CD4+ T cells in the FRT and CVS in comparison to PB.
HIV infection results in increased numbers of human CD4+ and
CD8+ T cells in CVS of BLT mice. As indicated above, HIV infection
894
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in humans and BLT mice results in a dramatic decrease in the levels of CD4+ T cells in the FRT and CVS that is not reflected in PB.
In previous studies, no determination was made about whether
the observed decrease in CD4+ T cells in the FRT was due to a
reduction in the number of CD4+ T cells and/or an increase in the
number of CD8+ T cells (33, 49, 50). To address this important
question, we performed a longitudinal analysis of CD4+ and CD8+
T cell numbers in CVS following HIV infection. Regardless of the
route of exposure (vaginal, rectal, or oral) or type of inoculum, we
observed significant increases in the numbers of both CD4+ and
CD8+ T cells in CVS, albeit with different kinetics (Figure 5, A–C).
Specifically, the increase in CD4+ T cells occurred during weeks
1–2 after infection and was somewhat modest (5- to 13-fold for
each of the 3 exposure routes). In sharp contrast, the increase in
the number of CD8+ T cells occurred later at weeks 2–7 and was
much greater (231-, 218-, and 56-fold after vaginal, oral, and rectal infections, respectively). These results demonstrate that the
reduction in the percentages of CD4+ T cells observed in CVS of

The Journal of Clinical Investigation  
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Figure 2. Human memory T cells expressing CCR5 are the main human hematopoietic cell population in CVS and the FRT of BLT mice. (A) Flow cytometric analyses of cells from the PB, FRT, and CVS of a representative HIV– BLT mouse demonstrate reconstitution with human CD4+ and CD8+ T cells in each
compartment. (B and C) Further characterization of T cells in PB (dots), the FRT (diagonal stripes), and CVS (solid color). Box plot showing the percentages
of CD4+ (blue) and CD8+ T cells (red) in PB (n = 60), the FRT (n = 6), and CVS (n = 57) of HIV– BLT mice. The middle line of the box plot is the median; box
extends from the 25th to the 75th percentiles, and error bars extend down to the lowest value and up to the highest value (B). CD4+ and CD8+ T cells in PB
(n = 9), the FRT (n = 4), and CVS (n = 46, CD4+ T cells; n = 37, CD8+ T cells) were analyzed for CCR5 expression with flow cytometry (C). (D and E) Bars represent mean values (± SEM). Further flow cytometric analyses characterizing the CD4+ (D) and CD8+ (E) T cell subsets. Naive T cells (CD45RA+CD27+), green;
CM T cells (CD45RA–CD27+), pink; and EM T cells (CD45RA–CD27–), purple. Bars represent mean values for PB (n = 26), the FRT (n = 4), and CVS (n = 60, CD4+
T cells; n = 41, CD8+ T cells). Data represented as mean ± SEM. A Mann-Whitney U test with a Holm-Bonferroni step-down correction was used to compare
the frequencies of immune cell populations within and between the PB, FRT, and CVS of BLT mice (*P < 0.05, **P < 0.01, ****P < 0.0001) (C–E).

HIV-infected BLT mice (Figure 4) was the result of a significant
increase in the levels of CD8+ T cells present in the CVS.
ART efficiently suppresses HIV in CVS and restores CD4+ and
CD8+ T cell numbers. In order to examine the effect of ART on
HIV levels and CD4+ and CD8+ T cell numbers in CVS, we treated
infected mice with an ART regimen that consisted of TDF, emtricitabine (FTC), and raltegravir (RAL). This triple-drug combination
has been shown to strongly suppress viral load in both humans and
BLT mice with continuous dosing (51–53). However, ART discontinuation in patients results in a rapid rebound of plasma viremia
as well as a loss of PB CD4+ T cells (54, 55). These phenomena are
also fully recapitulated in BLT mice (53, 56). In BLT mice infected
vaginally with cell-associated virus (Supplemental Table 1), ART
administration resulted in a dramatic and sustained decrease in
viral load in both plasma and CVS as early as 2 weeks after ART
initiation (Figure 6A). Analysis of CD4+ T cells in PB and CVS from
these mice prior to ART demonstrated the characteristic steep

decrease in the percentage of CD4+ T cells in CVS described above
and the less pronounced decrease observed in PB. During ART,
there was a dramatic increase in the percentage of CD4+ T cells in
CVS and an increase in the percentage of CD4+ T cells in PB (Figure 6B). These findings are in agreement with the fact that HIV+
women on ART have a significantly higher percentage of cervical
CD4+ T cells than infected women not receiving treatment (57).
In addition — as indicated above — prior to treatment, there was
a dramatic increase in total CD8+ T cells in CVS (Figure 6C). However, in response to ART, there was a rapid and substantial decrease
in the numbers of CD8+ T cells in this compartment. In contrast,
while the numbers of CD8+ cells decreased, the numbers of CD4+
T cells increased, resulting in the eventual return to near-normal
levels (Figure 6C). These results reveal that the observed increase
in the percentage of CD4+ T cell in CVS during ART (Figure 6B) was
caused by a concurrent decrease in the numbers of CD8+ T cells
and an increase in the numbers of CD4+ T cells.
jci.org   Volume 126   Number 3   March 2016
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Figure 3. HIV is present in the FRT and CVS of infected BLT mice, and the kinetics of HIV-RNA in CVS is similar to the kinetics of HIV-RNA in
PB plasma. (A) Immunohistochemical analysis of the FRT (vagina, cervix, and uterus) from one vaginally HIV-infected BLT mouse (3 weeks after
exposure). HIV p24 gag–positive cells are stained brown. Scale bars: 100 μm. (B–D) HIV-RNA was detected in the plasma (black solid line, filled
circles), and CVS supernatant (black dashed line, open circles) following vaginal (B) (n = 21), rectal (C) (n = 16), and oral (D) (n = 14) exposure. (E)
Comparison of the viral load in plasma and CVS supernatant of all routes combined (mice infected vaginally, rectally, and orally combined; n = 51).
The assay limit of detection is indicated with a dashed gray line. (B–E) Data represented as mean ± SEM. Associations between plasma and CVS
supernatant viral loads were estimated with Spearman’s correlation coefficient.

We next determined if ART suppression of cell-free HIV-RNA
levels observed in plasma and CVS (Figure 7A) parallels a similar
decrease in the levels of cell-associated HIV in PB, CVS, and the
FRT. For this purpose, we isolated cells from PB, FRT, and CVS
and analyzed their levels of cell-associated HIV-RNA (Figure 7B).
Our results show that ART significantly decreased the amount of
cell-associated HIV-RNA in all 3 compartments (PB ART vs. No
ART, P = 0.0009; FRT ART vs. No ART, P = 0.0002; and CVS ART
vs. No ART, P = 0.015) (Figure 7B). However, cell-associated HIVRNA remained readily detectable in the FRT and/or CVS of the
majority of mice undergoing ART. Therefore, despite the strong
reduction in the levels of cell-free HIV-RNA in mice receiving
ART, our analysis reveals an important dichotomy between the
suppression of cell-free HIV-RNA levels observed in CVS and the
continued presence of residual levels of cell-associated HIV-RNA
in the FRT/CVS. To determine whether these residual HIV-RNA+
896
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cells constitute an important source of infectious virus, we established a sensitive coculture assay to measure the number of infectious cells in PB, CVS, and the FRT of infected mice receiving ART
(Figure 7, C and D). Our results showed (i) that infectious cells were
readily detected in PB, CVS, and the FRT of infected BLT mice; (ii)
that ART suppresses the number of infectious cells in each of these
3 compartments; and (iii) that this reduction was statistically significant (P = 0.04) (Figure 7D). Thus, our results demonstrate that
ART efficiently suppresses levels of cell-free HIV and infectious
cells in PB, CVS, and the FRT. Most importantly, we then determined if ART suppresses the number of HIV-RNA+ cells in the PB,
CVS, and FRT of BLT mice to levels below those needed to prevent
secondary mucosal HIV transmission. We assessed the ability of
HIV-infected cells to establish infection in vivo by vaginally exposing BLT mice to 2 different doses of HIV-infected PB mononuclear
cells (PBMCs) and monitoring their plasma level of HIV-RNA for

The Journal of Clinical Investigation  
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Figure 4. After vaginal, rectal, or oral HIV infection, there is a decrease in the percentage of CD4+ T cells in CVS and the FRT. (A–C) The percentage
of CD4+ T cells in PB (filled diamond, solid line) and CVS (open triangle, dashed line) was measured in HIV– (n = 28) and vaginally (A) (n = 18), rectally
(B) (n = 11), or orally (C) (n = 12) infected BLT mice. Data is shown as mean ± SEM. A Mann-Whitney U test was used to compare CD4+ T cell levels
between the PB and CVS (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (D) Additional analysis of the percentage of CD4+ T cells in the FRT
was performed in HIV– BLT mice (n = 7); vaginally infected BLT mice (filled circle) at weeks 1 (n = 1), 3 (n = 1), 5 (n = 1), and 7 (n = 1); rectally infected
mice (asterisk) at weeks 6 (n = 2) and 10 (n = 1); and an orally infected mouse (filled square) at week 8 (n = 1) after exposure.

8 weeks. As shown in Figure 7E, all BLT mice exposed to 5,000
HIV-infected PBMCs remained negative for HIV-RNA. However,
50% of mice exposed to 10,000 HIV-infected cells became positive for plasma HIV-RNA. Our results revealed that the number
of HIV-RNA+ cells in all 3 compartments analyzed from ARTsuppressed BLT mice is well below what is needed to establish
vaginal HIV transmission in this model.

Discussion

In this manuscript, we provide data demonstrating (i) that
regardless of the route of infection (vaginal, rectal, or oral) and
whether the inoculum is cell-free or cell-associated HIV, local
viral replication occurs in the FRT and CVS during acute HIV
infection, the time when secondary transmission is most likely to
occur (Figure 3); (ii) that this is followed by a transient increase
in CD4+ T cell levels in CVS that can serve to provide additional
target cells to sustain or promote infection (Figure 5); and (iii)
that this is itself followed by a somewhat delayed increase in
CD8+ T cell levels in CVS (Figure 5). In addition, our study provides in vivo evidence supporting the hypothesis behind the success of HPTN 052 (12): that initiating ART can reduce the risk
of secondary HIV transmission by efficiently suppressing HIV
levels in the genital tract (Figures 6 and 7).
Interestingly, our results also highlighted a potentially important dichotomy between the levels of cell-free virus and cellassociated HIV-RNA in the FRT and CVS of ART-suppressed
mice. Specifically, in animals with undetectable cell-free HIVRNA in plasma and CVS, significant levels of HIV-infected cells

producing viral RNA remain in the FRT and CVS of some ARTtreated mice (Figure 7). The presence of cell-associated HIV-RNA
has been demonstrated in other secretions of ART-suppressed
women. Valea et al. demonstrated the presence of cell-associated
HIV-RNA in breast milk obtained from ART-treated mothers with
undetectable levels of cell-free HIV-RNA in plasma and breast
milk (58). These results are in agreement with our observations in
BLT mice demonstrating that cell-associated HIV-RNA can persist in mucosal secretions despite ART. Collectively, our results
and those of Valea et al. may have important implications for
the design of effective HIV prevention and curative approaches.
In the future, it will be important to determine if cell-associated
HIV-RNA persists in other mucosal secretions and tissues despite
suppression of cell-free HIV-RNA.
Worldwide, the majority of new HIV infections occur after
heterosexual exposure (59). In vaginally exposed women, the
primary ports of HIV entry are the mucosal surfaces of the
vagina, cervix, and uterus (60–62). The identity and the location
of the initial cells involved in HIV-1 transmission are a subject
of great debate (29). The DC–T cell milieu is a highly permissive site for virus growth, and DCs likely contribute to driving
the productive infection in CD4+ T cells (63–67). Hence, both
intraepithelial Langerhans cells and DCs have potential important roles in vaginal HIV transmission (65–69). However, the
mucosa of the human FRT contains an abundance of CD4+
T cells (24, 25, 34, 68), and experiments in both NHPs (nonhuman primates) and human explant models suggest that the
first productively infected cells are likely T cells (61, 68, 70–73).
jci.org   Volume 126   Number 3   March 2016
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Figure 5. After vaginal, rectal, or oral HIV infection, there is an increase of CD8+ and CD4+ T cells in CVS. (A–C) The CD8+ (filled upward triangle, dashed
red line) and CD4+ T cell numbers (filled downward triangle, blue dashed line) in CVS were measured in HIV– (n = 28) and vaginally (A) (n = 18), rectally (B)
(n = 11), or orally (C) (n = 4) infected BLT mice. Data presented as mean ± SEM. Statistical analysis represents comparisons of the weeks indicated vs. the
numbers of CD4+ or CD8+ T cells in naive mice. A Mann-Whitney U test was used to compare the numbers of CD4+ and CD8+ T cells in the CVS of naive and
HIV-infected BLT mice (**P < 0.01, ***P < 0.001, ****P < 0.0001).

Regardless, each of the most relevant human HIV target cells
(CD4+ T cells, macrophages, and DCs) are present throughout
the entire FRT of BLT mice (Figure 1, Supplemental Figures 1 and
2, and ref. 21). Reconstitution of the FRT of BLT mice with the
appropriate human hematopoietic cells renders BLT mice susceptible to vaginal HIV transmission (21). The susceptibility of
BLT mice to vaginal HIV infection has allowed this model to be
used to evaluate novel approaches of HIV prevention (21, 23, 74).
In this manuscript, we utilized BLT mice to elucidate and study
critical events occurring in the FRT and CVS during HIV infection.
Specifically, by performing comprehensive analyses of the T cell
subsets present in the FRT and CVS, we have gained insight into
the human immune cell populations in this organ. Consistent with
observations made in healthy women, the majority of the human
lymphocytes present in both the FRT and CVS of BLT mice are
memory T cells (Figure 2D and refs. 31, 32). Also, consistent with
the preferential vaginal transmission of CCR5-tropic viruses, a high
percentage of CD4+ T cells present in the FRT and CVS express
CCR5 (Figure 2C and refs. 31, 32). Furthermore, consistent with
humans, a significant number of the memory CD4+ T cells present
in the FRT and CVS of BLT mice expressed α4β7 (Supplemental
Figure 3). The similarities between the phenotypes of hematopoietic
cells present in the FRT of humans and BLT mice emphasize the
utility of BLT mice as an in vivo model for the study of events occurring at the site where HIV exposure occurs.
Our results demonstrating parallel reductions in the percentage of CD4+ T cells in the FRT and CVS of BLT mice indicate
that the cell populations are closely linked throughout the course
of infection (Figure 4). These striking similarities between the
dynamics of T cells present in CVS and the FRT after HIV infection suggest that cells from CVS could be potentially used as a surrogate for monitoring some of the changes that occur in the FRT.
Thus, these results may have significant implications that could
facilitate and simplify future studies of transmission and prevention in both humans and in NHP models by minimizing the need
to harvest or biopsy the FRT.
In order to study the dynamics of human CD4+ and CD8+ T
cells and viral replication that occur in the FRT after vaginal HIV
infection, we vaginally exposed BLT mice to HIV. Our results
demonstrate an increase of CD4+ T cells in CVS during the first
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2 weeks after infection (Figure 5A), providing additional HIV
target cells to sustain and potentially spread the initial infection.
These results are consistent with HIV-RNA being present in CVS
within 1 week after exposure (Figure 3B), suggesting that local
HIV replication occurs in the FRT and/or CVS followed by the
establishment of systemic infection in all mice by 2 weeks after
exposure (Figure 3B). Especially noteworthy is the timing of viral
shedding into CVS after vaginal exposure, which is characterized
by an early peak in viremia followed by a gradual decline (Figure 3B) that mimics the HIV genital shedding profile observed
in CVS of women during acute HIV infection (39). Notably, we
also observed an increase in CD8+ T cells in CVS after vaginal
infection (Figure 5A). However, in contrast to the increase of
CD4+ cells occurring within one to 2 weeks after exposure, the
increase of CD8+ T cells was first detected 2 weeks after exposure
and did not peak until week 5–7 (Figure 5A). These results are
consistent with reports from vaginal-infection studies in NHPs
demonstrating that initial SIV infection takes place in a few CD4+
T cells, resulting in local inflammation and recruitment of additional CD4+ T cells (61, 72, 75). Clusters of SIV-infected cells are
present within inflammatory infiltrates, which increase in size
during days 4–10 after exposure (61, 72, 75). In addition, genital CD8+ T cell influx was detected 2–3 weeks after vaginal SIV
infection of NHPs, a time by which all animals had become systemically infected (72, 76). Thus, the timing of CD4+ and CD8+
T cell increase in CVS, as well as the timing of local viral replication and systemic infection that we have observed in BLT mice,
is strikingly similar to NHPs. Together, these results support the
hypothesis that the increase of CD8+ T cells in the CVS/FRT is
delayed after exposure, potentially preventing effective suppression of HIV replication at early stages after exposure (75, 76).
We next investigated the effect of ART on HIV levels in CVS of
BLT mice. Consistent with results obtained in humans, ART treatment of infected BLT mice resulted in a significant decrease in the
levels of HIV in both PB and CVS (15, 16). However, our finding
showing the absence of cell-free HIV in CVS during ART, concurrent
with the continued presence of infected cells producing HIV-RNA,
could have important implications for HIV prevention and eradication strategies. Consistent with the lack of transmission observed
in heterosexual couples where the infected partner is undergoing
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Figure 6. ART suppresses HIV-RNA in the plasma and CVS, leading to a reduction in the number of CD8+ T cells and an increase of CD4+ T cells in CVS.
Six HIV-infected BLT mice were treated with daily ART consisting of FTC, TDF, and RAL to evaluate the effect of ART on HIV-RNA levels in the plasma and
CVS supernatant, as well as T cell levels in PB and CVS. ART was initiated in BLT mice 6–8 weeks after HIV exposure. Time point 0 corresponds to the day
of ART initiation, and the time points corresponding to ART are shaded gray. (A) Viral load analyses of the plasma (black solid line, filled circles) and CVS
supernatant (black dashed line, open circles). The assay limit of detection is indicated with a dashed gray line. (B) The percentage of CD4+ cells in PB (filled
diamond, blue solid line) and CVS (open downward triangle, blue dashed line). (C) The number of CD4+ (filled downward triangle, blue dashed line) and
CD8+ (filled upward triangle, dashed red line) T cells in CVS. Data represented as mean ± SEM.

ART (12), our analysis showed that the residual levels of HIV-RNA+
cells present in mice receiving ART were too low to transmit HIV in
vitro. This lack of HIV transmission could have been due to too few
infected cells for cell-to-cell transmission and/or too little cell-free
replication–competent virus produced from the residual HIV-RNA+
cells for in vitro infection of target cells. The residual levels of HIVRNA+ cells detected in the CVS and FRT of ART-suppressed mice
were well below the number of HIV-infected cells required for HIV
transmission in BLT mice. The availability of a small animal model
that so accurately recapitulates key aspects of the human condition
represents a unique tool for the in vivo study of the intricate cellular dynamics occurring during HIV infection in the FRT and to
address critical questions in the field, such as whether cell-to-cell
transmission contributes sexual transmission of HIV or whether
all transmission is via cell-free, replication-competent virions. In
addition, this model could prove helpful in the evaluation of novel
approaches to prevent cell-free and cell-associated HIV transmission.

Methods
Generation of BLT mice
BLT mice were prepared essentially as previously described (19–23).
Briefly, BLT mice were individually bioengineered by transplanting
(BM transplant) human fetal liver–derived CD34+ hematopoietic
stem cells into NOD/SCID/γc –/– mice (stock number 00557, NSG
mice; The Jackson Laboratory) implanted with autologous human
liver and thymus tissue (Advanced Bioscience Resources). A sandwich of 1- to 2-mm pieces of human thymus-liver-thymus tissue was
implanted under the kidney capsule of 6- to 14-week-old female NSG
mice. Mice were exposed to sublethal γ irradiation (300 cGy) 4–24
hours prior to the transplantation of CD34+ stem cells (2.5–8 × 105
CD34+ cells) to facilitate BM engraftment.
Immunohistochemical analyses
Immunohistochemical analyses were performed on paraffinembedded FRT sections. FRTs for IHC were harvested from BLT

mice, fixed in 4% paraformaldehyde overnight at 4°C, embedded
in paraffin, cut into 5-μm sections, and mounted onto poly-l-lysine–
coated glass slides. Following paraffin removal, antigen retrieval
(Diva Decloaker, Biocare Medical), and blocking of nonspecific
Ig–binding sites (Background Sniper, Biocare Medical), tissue sections were stained with primary antibodies overnight at 4°C and developed with a biotin-free HRP-polymer system (MACH3 Mouse HRPPolymer Detection, Biocare Medical). All tissue sections were treated
with HRP substrate (ImmPACT DAB, Vector Laboratories) and then
counterstained with hematoxylin. Primary antibodies specific for
human CD4 (clone 1F6, Leica Biosystems), human CD68 (clone KP1,
Dako), and human CD11c (clone 5D11, Leica Biosystems) were used
to identify human cells (24, 77–81). HIV-infected cells were detected
with an antibody directed against HIV p24 gag (clone Kal-1, Dako).
As a control, tissue sections were stained with the following isotype
control antibodies: mouse IgG1 (clone DAK-G01, Dako) and mouse
IgG2a (clone DAL-G02, Dako). The stained sections were scanned
by ScanScope CS (Aperio, Leica Biosystems) and the images were
then analyzed by ImageScope (Aperio, Leica Biosystems).

Flow cytometric analyses
Flow cytometric analyses were performed on PB, FRT, and CVS cells.
CVS samples were obtained by performing a cervicovaginal lavage
with sterile PBS (3 washes of 20 μl each, ~60 μl total volume). To
ensure that the procedure was atraumatic, cervicovaginal lavages
were performed with 20 μl or 200 μl sterile filter pipet tips that were
inserted no more than 3–5 mm into the vaginal cavity. Following centrifugation in a microcentrifuge (300 g for 5 minutes), CVS cell-free
supernatants were used for HIV-RNA analyses and the cell pellets
were used for flow cytometric analyses. The CVS samples contained
a highly variable number of total cells (due to variable cell shedding).
Therefore, the human CD3+ T cell numbers in CVS were normalized
to 100,000 total cells. FRTs were harvested and digested, and single
cell suspensions were isolated as previously described (23). BLT mice
were monitored for levels of human hematopoietic cells (CD45+)
in PB by flow cytometry, as we have previously described (19–23).
jci.org   Volume 126   Number 3   March 2016
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Figure 7. ART suppresses cell-free HIV-RNA in CVS and PB but does not consistently suppress cell-associated HIV-RNA in the FRT and CVS. (A) Viral
load analyses of the plasma (black solid line, filled circles) and CVS supernatant (black dashed line, open circles) demonstrated sustained viral load
in the plasma and CVS supernatant of 8 HIV-infected ART-naive mice (left panel) and a dramatic decrease in viral load to undetectable levels in both
plasma and CVS supernatant in 5 representative ART-treated mice (right panel). Time points corresponding to ART are shaded gray. (B) Cell-associated
HIV-RNA in the PB, FRT, and CVS of mice receiving ART for 5–8 weeks (n = 8) and of ART-naive mice (No ART) (n = 8). RNA was isolated from mononuclear cells, and the RNA determination for each sample was performed in triplicate. (C) The level of infectious cells in PB and CVS from BLT mice was
determined in 8 ART-treated mice and 5 ART-naive mice. Samples from all mice in each group (ART vs. No ART) were pooled at each time point: week –1
(ART n = 8, No ART n = 5), week 2 (ART n = 4, No ART n = 5), and week 3 (ART n = 3, No ART n = 5). (D) The level of infectious cells in the FRT of mice
treated with ART for 5 weeks and in ART-naive mice (ART n = 4, No ART n = 5). (B–D) Bars represent mean values. Data are represented as ± SEM. (C
and D) Limit of detection was 2 infectious units per 1 × 106 cells. (E) BLT mice were exposed vaginally to 2 different doses of HIV-infected PBMC (open
symbols: 5,000 PBMC, n = 4; closed symbols: 10,000 PBMC, n = 4). Plasma levels of HIV-RNA were monitored for 8 weeks. A Mann-Whitney U test was
used to compare levels of cell-associated HIV-RNA and infectious cells between ART-naive and ART-treated mice (*P < 0.05, ***P < 0.001) (B and D).
The assay limit of detection is indicated with a dashed gray line.

The antibody clones included in the flow cytometry panels that
were used to analyze PB and cells isolated from the FRT and CVS
of BLT mice are as follows: Panel A – CD3 FITC (HIT3a), CD4 PE
(RPA-T4), CD8 PerCP (SK1), and CD45 APC (HI30); Panel B – CD8
FITC (SK1), CXCR4 PE (12G5) or IgG2ακ PE (G155-178), CD4 PerCP
(SK3), CD3 PE-Cy7 (SK7), CCR5 APC (3A9) or IgG2ακ APC (G155178), and CD45 APC-Cy7 (2D1); Panel C – CD45RA FITC (HI100)
or IgG2 FITC (27-35), CD27 PE (M-T271) or IgG1κ PE (MPOC-21),
CD8 PerCP (SK1), CD3 PE-Cy7 (SK7), CD45 APC (HI30), and
CD4 APC-H7 (RPA-T4); Panel D – CD27 FITC (M-T271) or IgG1k
FITC (MOPC-21), α4β7 PE (ACT-1) or IgG1k PE (P3.6.2.8.1), CD8
900
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PerCP (SK1), CD3 PECy7 (SK7), CD45 APC (H130), CD4 APC-H7
(RPA-T4), and CD45RA Pacific Blue (F8-11-13) or IgG1k Pacific Blue
(MOPC-21). All antibodies were purchased from BD Biosciences,
except for CD45RA Pacific Blue (AbD Serotec), unconjugated IgG1k
(eBioscience), and unconjugated α4β7 (ACT-1, catalog 11718) (NIH
AIDS Research and Reference Reagent program) (82). The unconjugated α4β7 (ACT-1) and isotype IgG1k antibodies were labeled with
PE using the LYNX Rapid RPE antibody conjugation kit (AbD Serotec). Gates defining CD27, CD45RA, CCR5, and α4β7 expression
were set with isotype-matched fluorophore-conjugated antibodies.
In Figure 2B, to account for the differential presence of NKT cells
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that are CD3+ but lack expression of CD4 and CD8, the percentage of
CD4+ and CD8+ T cells in PB, CVS, and FRT was calculated by dividing the number of CD3+ T cells that expressed CD4 or CD8 by the
total number of CD3+ T cells that expressed either CD4 or CD8. Flow
cytometric data collection and analyses were performed using a BD
FACS Canto or Fortessa cytometer and FACSDiva software.

Exposure of BLT mice to HIV and treatment with ART
BLT mice were infected vaginally, rectally, or orally with cell-free or
cell-associated CCR5 tropic HIV-1 essentially as previously described
(19–23, 45, 47).
Cell-free HIV exposures. Stocks of HIV-1JR-CSF or HIV-1RHPA were
prepared and tittered using TZM-bl cells (AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of
Allergy and Infectious Diseases) as previously described (19–23).
BLT mice were exposed vaginally to 3 × 105 –3.5 × 105 tissue culture infectious units (TCIU), rectally to 3.5 × 105 –4.8 × 106 TCIU, or
orally to 1.4 × 106 TCIU of HIV-1.
Cell-associated HIV exposures. Human PBMCs were infected in
vitro with HIV-1JR-CSF. PBMCs were cultured in the presence of IL-2
and PHA for 3 days and then inoculated at a MOI of 0.1 with HIV1JR-CSF by a 2-hour spin infection. Next, PBMCs were washed 3 times,
resuspended in IMDM medium, and — 3–4 days after inoculation —
the percentage of HIV-infected cells was determined by intracellular staining for p24 gag (clone KC57-FITC, Beckman-Coulter) using
the Fix and Perm kit (Invitrogen). BLT mice were vaginally exposed
to 1 × 105 HIV p24 gag+ PBMCs (up to 1.9 × 107 total PBMCs) or orally
to 3.75 × 105 HIV p24 gag+ PBMCs (up to 1.6 × 107 total PBMCs).
Vaginal exposure to cell-associated HIV was performed by administering 5,000 or 10,000 HIV-1 p24+ cells in a volume of 10 μl to
anesthetized BLT mice. We did not observe any phenotypic differences when using HIV-1JR-CSF or HIV-1RHPA for exposures or when
using cell-free virus versus cell-associated virus. HIV-infected BLT
mice designated for treatment received daily ART (by i.p. injection)
consisting of FTC (140–200 mg/kg body weight), tenofovir disoproxil fumarate (TDF; 146–208 mg/kg), and RAL (56–80 mg/kg),
as we have previously described (53). ART was administered for an
average of 5.6 weeks (range 4–8 weeks). No overt drug-associated
toxicity was observed.
Real-time PCR for HIV-RNA
Infection of BLT mice with HIV was monitored in plasma and CVS
supernatant by determining levels of cell-free HIV-RNA using
one-step quantitative PCR (qPCR) (ABI custom TaqMan Assaysby-Design) according to the manufacturer’s instructions (primers
[5′-CATGTTTTCAGCATTATCAGAAGGA-3′ and 5′-TGCTTGATGTCCCCCCACT-3′] and MGB-probe [5′FAM-CCACCCCACAAGATTTAAA CACCATGCTAA-Q 3′ (83)]) as previously described,
with a limit of detection of 750 HIV-RNA copies per ml (53). The
lower sensitivity of our standard assay compared with that of the
standard clinical assay (50 copies per ml) is due to the lower volume
of plasma that can be obtained routinely from mice. The levels of
cell-associated HIV-RNA were analyzed in mononuclear cells isolated from PB, FRT, and CVS. HIV-RNA was extracted from mononuclear cells (RNeasy Mini Kit, QIAGEN), and a one-step qPCR
was performed as described above. For all analyses, cell-free and
cell-associated HIV-RNA measures were log10 transformed.

Replication competence of HIV in cells from the PB, CVS, or FRT of
infected BLT mice
The replication competence of virus present in cells obtained from
infected BLT mice was determined using a coculture assay. For this
purpose, cells isolated from PB, CVS, or the FRT of infected animals were cocultured with TZM-bl indicator cells in the presence of
DEAE-dextran (Sigma-Aldrich) (2 μg/ml) for 24 hours. The culture
medium was then removed and replaced with fresh medium. Cells
were incubated for an additional 48 hours, fixed, and stained for
β-galactosidase activity. Individually infected cells were manually
counted under an inverted microscope. The limit of detection was
two infectious units per 1 × 106 cells.
Statistics
Bivariate statistical comparisons were performed using the 2-sample
Mann-Whitney U test. The Bonferroni step-down (Holm) correction
was used to adjust for multiple testing for sets of related hypothesis
tests in Figure 2 and Supplemental Figure 3. Data in Figure 2 and
Supplemental Figure 3 were analyzed as independent observations.
Some of the PB and CVS data in Figure 2 represent multiple longitudinal time points from the same animal (Figure 2, B, D, and E) and/
or paired observations (Figure 2, B–E). In addition, some of the PB
data in Supplemental Figure 3 represent multiple longitudinal time
points from the same animal and/or are paired with CVS and/or FRT
data. Collectively, PB and CVS data were obtained from 30 mice for
Figure 2B (n = 30, PB; n = 30, CVS), 20 mice for Figure 2C (n = 9, PB;
n = 19, CVS), 29 mice for Figure 2D (n = 9, PB; n = 26, CVS), and 18
mice for Figure 2E (n = 9, PB; n = 15, CVS). The data in Supplemental
Figure 3 represents a total of 21 BLT mice (n = 16, PB; n = 13, CVS; and
n = 5, FRT). Associations between viral load in plasma and CVS supernatant were estimated with Spearman’s correlation coefficient. Correlation estimates were calculated at each time point, and an average
correlation was computed by taking a weight average of time-specific
estimates (84). The bootstrap (85) was used to calculate CIs for the
average correlation and to assess whether the average correlation
was nonzero. Analyses were conducted using R version 2.13, GraphPad Prism version 5.0, and SAS version 9.4. P < 0.05 were considered
significant. Statistically significant results in figures are indicated as
follows: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Study approval
Mice were maintained at the Division of Laboratory Animal Medicine
at the UNC Chapel Hill in accordance with protocols approved by the
Institutional Animal Care and Use Committee.
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